H3n2 Infection Pipeline Insight
DelveInsight’s, “H3N2 Infection - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in H3N2 Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
H3N2 Infection Understanding
H3N2 Infection: Overview
H3N2 viruses have circulated in humans since their pandemic emergence in 1968 and are generally associated with uncomplicated disease in young healthy adults. However, epidemics caused by H3N2 viruses have been more severe than those caused by seasonal H1N1 or influenza B viruses. Influenza viruses that normally circulate in pigs are called “variant” viruses when they are found in people. Influenza A H3N2 variant viruses (also known as “H3N2v” viruses) with the matrix (M) gene from the 2009 H1N1 pandemic virus were first detected in people in July 2011. H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2.A H3N2 viral susceptibility.
"H3N2 Infection - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the H3N2 Infection pipeline landscape is provided which includes the disease overview and H3N2 Infection treatment guidelines. The assessment part of the report embraces, in depth H3N2 Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in H3N2 Infection R&D. The therapies under development are focused on novel approaches to treat/improve in H3N2 Infection.
- In September 2021, NanoFlu achieved the trial's primary endpoints, demonstrating non-inferior immunogenicity to Fluzone® Quadrivalent against all four influenza virus strains included in the vaccine, while also showing both enhanced wild-type hemagglutination-inhibiting antibody responses against homologous strains (22-66% increased) and six heterologous A/H3N2 strains (34-46% increased) as compared to Fluzone Quadrivalent.
H3N2 Infection Emerging Drug Chapters
This segment of the H3N2 Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
H3N2 Infection Emerging Drugs
NanoFlu: Novavax
NanoFlu is our quadrivalent nanoparticle influenza vaccine (qNIV) candidate, targeting seasonal flu. NanoFlu is designed using our recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.
PrEP-001: PrEP Biopharm
PrEP-001, is an immunomodulator in Phase 2 for the prevention of influenza, influenza-like-illness and the common cold. These upper respiratory viral infections (URVIs) drive significant disease burden particularly for patients with underlying respiratory disorders (eg asthma and COPD) or weakened immune systems (eg the elderly). A nasally delivered powder containing a viral RNA surrogate, PrEP-001, triggers the innate immune system via the Rig-I, MDA5 and TLR3 receptors and is expected to provide a rapid, broad-spectrum prophylaxis against ~200 respiratory viruses. PrEP-001 is anticipated to be a first-to-market prophylactic nasal spray that creates a novel paradigm of prevention against these URVIs.
Further product details are provided in the report……..
H3N2 Infection: Therapeutic Assessment
This segment of the report provides insights about the different H3N2 Infection drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in H3N2 Infection
There are approx. 20+ key companies which are developing the therapies for H3N2 Infection. The companies which have their H3N2 Infection drug candidates in the most advanced stage, i.e. Phase II include Ansun Biopharma.
Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
H3N2 Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Monoclonal Antibody
- Immunotherapy
- Vaccines
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
H3N2 Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses H3N2 Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging H3N2 Infection drugs.
H3N2 Infection Report Insights
- H3N2 Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
H3N2 Infection Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing H3N2 Infection drugs?
- How many H3N2 Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of H3N2 Infection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the H3N2 Infection?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for H3N2 Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
H3N2 Infection: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Treatment
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
H3N2 Infection – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
- Comparative Analysis
DAS181: Ansun Biopharma
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
- Comparative Analysis
CD388: Cidara Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
- Comparative Analysis
Astodrimer: Starpharma
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
- Comparative Analysis
H3N2 Infection Key Companies
H3N2 Infection Key Products
H3N2 Infection - Unmet Needs
H3N2 Infection - Market Drivers and Barriers
H3N2 Infection - Future Perspectives and Conclusion
H3N2 Infection Analyst Views
H3N2 Infection Key Companies
Appendix
List of Table
Table 1: Total Products for H3N2 Infection
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for H3N2 Infection
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Emergent BioSolutions
• Aphios
• Ansun Biopharma
• Starpharma
• Cidara Therapeutics
• Medicago
• Novavax
• PrEP Biopharm
• Sciogen
• CureVac